Propanc Biopharma, Inc. PPCB NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • AU • USD

SharesGrow Score

28/100

0/4 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Propanc Biopharma, Inc. (PPCB) reported total assets of $19.63M and total liabilities of $5.73M for fiscal year 2025, resulting in total equity of $13.91M.

The company held $12.09K in cash and short-term investments. Total debt stood at $1.73M, with net debt of $1.71M. The Debt-to-Equity (D/E) ratio was 0.12 (conservative).

Current ratio is 1.5, indicating strong short-term liquidity. Interest coverage is -101.6x (weak).

Criteria supported by this page:

HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
MOAT (28/100) — Total assets $19.63M and equity $13.91M support the company's competitive scale

Overall SharesGrow Score: 25/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

28/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

28/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Propanc Biopharma, Inc. Balance Sheet History

Metric	FY2025	FY2024	FY2023	FY2022
Total Assets	$19.63M	$72.37K	$60.33K	$81.65K
Total Liabilities	$5.73M	$3.85M	$3.18M	$3.11M
Total Debt	$1.73M	$948.27K	$545.92K	$1.04M
Cash & Investments	$12.09K	$21.09K	$10.05K	$4.07K
Total Stockholders Equity	$13.91M	$-3.78M	$-3.12M	$-3.02M